Anti-Mouse EpCAM (CD326) In Vivo Antibody

Product Name:	Anti-Mouse EpCAM (CD326) In Vivo Antibody - Ultra Low Endotoxin
Product Code:	IVMB0256
Size:	1 mg, 5 mg, 25 mg, 50 mg, 100 mg
Clone:	G8.8
Product Type:	Hybridoma Monoclonal Antibody
Synonyms:	EGP314
Isotype:	Rat IgG2a k
Reactivity:	Human, Mouse
Applications:	FC, IF, IHC, IP, WB
Formulation:	This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Endotoxin Level:	<0.5 EU/mg as determined by the LAL method
Purity:	≥95% by SDS Page ⋅ ≥98% monomer by analytical SEC
Product Preparation:	Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

Applications:	FC, IF, IHC, IP, WB
Reactivity:	Human, Mouse

Host Species:	Rat
Specificity:	G8.8 activity is directed against mouse EpCAM (CD326) and does not recognize human or rat EpCAM.
Antigen Distribution:	EpCAM is expressed in many epithelial tissues from very early embryos to adult animals and is a cell surface marker on various stem and progenitor cells. EpCAM is also an important carcinoma marker highly expressed on a variety of carcinomas, including epithelial tumors and acute myeloid leukemia. EpCAM is enriched in the basolateral membrane of mouse and human intestinal epithelium and is localized to tight junctions, adherens junctions, and the lateral membranes of epithelial cells lining the intestines.
Immunogen:	TE-71 thymic epithelial cell line
Concentration:	≥ 5.0 mg/ml
Endotoxin Level:	<0.5 EU/mg as determined by the LAL method
Formulation:	This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Purity:	≥95% by SDS Page ⋅ ≥98% monomer by analytical SEC
Preparation:	Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Storage and Handling:	Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -70°C. Avoid Repeated Freeze Thaw Cycles.

Epithelial cell adhesion molecule (EpCAM; also known as CD326 or Tacstd1) is a 40 kDa type I transmembrane glycoprotein composed of an extracellular domain, single transmembrane domain, and the intracellular domain Ep1CD1. EpCAM functions in cell adhesion, signaling, differentiation, migration, proliferation, formation and maintenance of organ morphology, and morphogenic movements during gastrulation. Additionally, EpCAM is essential for cell junctions; the AxxxG motif in the transmembrane domain of EpCAM associates directly with claudin-7, an important tight junction protein. EpCAM also suppresses or enhances E-cadherin function depending on the context of the interaction. Mutant animal models have been developed in mouse (at least four global EpCAM knockout types and one conditional knockout), zebrafish, and Xenopus.

Dysregulation and/or mutations are associated with congenital tufting enteropathy (CTE), which causes lethal diarrhea in newborns, cholestatic liver diseases, and cancer1. EpCAM promotes the proliferation of tumors, is involved in tumorigenesis and metastasis, and EpCAM positive cells serve as cancer stem cells for various human cancers. Therapeutic approaches targeting EpCAM are under development to eliminate chemotherapeutic drug resistance in cancer stem cells by conjugating cancer stem cells targeting EpCAM aptamer with a chemotherapeutic drug. Additionally, EpCAM antibody sensitizes chemoresistant myeloid leukemia to innate immune cells, and EpCAM peptide-primed dendritic cell vaccinations exhibit anti-tumor immunity in hepatocellular carcinoma cells.

Monoclonal antibody G8.8 was raised against glycoconjugates isolated from the TE-71 mouse thymic epithelial cell line2. Splenic cell suspensions were fused with X63-Ag8.653 cells and the resulting hybridomas were screened on frozen Balb/c thymus.

Ligand/Receptor:	LAIR-1 (CD305) and LAIR-2 (CD306)
Research Area:	Cell Adhesion, Immunology
State of Matter:	Liquid
Shipping:	2-8°C
NCBI Gene Bank ID:	17075